Literature DB >> 18468747

Detection and awareness of moderate to advanced CKD by primary care practitioners: a cross-sectional study from Italy.

Roberto Minutolo1, Luca De Nicola, Giampiero Mazzaglia, Maurizio Postorino, Claudio Cricelli, Lorenzo G Mantovani, Giuseppe Conte, Bruno Cianciaruso.   

Abstract

BACKGROUND: Chronic kidney disease (CKD) is a strong independent predictor of cardiovascular disease. Although general practitioners (GPs) represent the first line for identification of these high-risk patients, their diagnostic approach to CKD is ill defined. STUDY
DESIGN: Cross-sectional evaluation of database of Italian GPs. SETTING & PARTICIPANTS: Representative sample of adult Italian population regularly followed up by GPs in 2003. OUTCOMES: Frequency of serum creatinine testing, prevalence of CKD (estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73 m(2)), awareness of CKD assessed from use of diagnostic codes (Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM]) for CKD, and referral to nephrologists.
RESULTS: Of 451,548 individuals in the entire practice population, only 77,630 (17.2%) underwent serum creatinine testing. Female sex (odds ratio [OR], 1.09; 95% confidence interval [CI], 1.06 to 1.12), advanced age (OR, 2.70; 95% CI, 2.63 to 2.78), diabetes (OR, 1.31; 95% CI, 1.20 to 1.42), hypertension (OR, 1.10; 95% CI, 1.02 to 1.19), autoimmune diseases (OR, 1.42; 95% CI, 1.11 to 1.82), and recurrent urinary tract infections (OR, 1.63; 95% CI, 1.10 to 2.42) were all associated with serum creatinine testing. Conversely, use of either nonsteroidal anti-inflammatory drugs (OR, 1.03; 95% CI, 0.89 to 1.21) or aminoglycosides or contrast media (OR, 0.78; 95% CI, 0.54 to 1.14) was not associated with serum creatinine testing. In the subgroup with serum creatinine data, the age-adjusted prevalence of CKD was 9.33% (11.93% in women, 6.49% in men). However, in patients with eGFR less than 60 mL/min/1.73 m(2), serum creatinine values were apparently normal (<1.2 mg/dL in women, <1.4 mg/dL in men) in 54%, and GPs used ICD-9-CM codes for CKD in only 15.2%. Referral to nephrologists ranged from 4.9% for patients with eGFR of 59 to 30 mL/min/1.73 m(2) to 55.7% for those with eGFR less than 30 mL/min/1.73 m(2). LIMITATIONS: The prevalence of decreased kidney function may be overestimated because of the more frequent serum creatinine testing in sicker individuals and lack of creatinine calibration.
CONCLUSIONS: In primary care, CKD stages 3 to 5 are frequent, but its awareness is scarce because of limited rates of serum creatinine testing and difficulty recognizing decreased eGFR in the absence of increased serum creatinine testing.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18468747     DOI: 10.1053/j.ajkd.2008.03.002

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  45 in total

1.  Primary care management of chronic kidney disease.

Authors:  Adrienne S Allen; John P Forman; E John Orav; David W Bates; Bradley M Denker; Thomas D Sequist
Journal:  J Gen Intern Med       Date:  2010-10-05       Impact factor: 5.128

Review 2.  Validation of CKD and related conditions in existing data sets: A systematic review.

Authors:  Morgan E Grams; Laura C Plantinga; Elizabeth Hedgeman; Rajiv Saran; Gary L Myers; Desmond E Williams; Neil R Powe
Journal:  Am J Kidney Dis       Date:  2010-08-06       Impact factor: 8.860

3.  Chronic kidney disease epidemic: myth and reality.

Authors:  Filippo Mangione; Antonio Dal Canton
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

4.  Health economic evaluation of paricalcitol(®) versus cinacalcet + calcitriol (oral) in Italy. [corrected].

Authors:  Mark Nuijten; Daniela P Roggeri; Alessandro Roggeri; Paolo Novelli; Thomas S Marshall
Journal:  Clin Drug Investig       Date:  2015-04       Impact factor: 2.859

5.  Significance of past history of renal failure for the detection of high-risk individuals for cardiovascular and end-stage renal disease: analysis of data from a nationwide health checkup.

Authors:  Kazunobu Ichikawa; Tsuneo Konta; Ami Ikeda; Shouichi Fujimoto; Kunitoshi Iseki; Toshiki Moriyama; Kunihiro Yamagata; Kazuhiko Tsuruya; Hideaki Yoshida; Koichi Asahi; Issei Kurahashi; Yasuo Ohashi; Tsuyoshi Watanabe
Journal:  Clin Exp Nephrol       Date:  2011-08-05       Impact factor: 2.801

6.  Detection of urinary abnormalities in a community from northern Italy based on the World Kidney Day screening program.

Authors:  F Fabbian; P L Bedani; E Rizzioli; C Molino; M Pala; A De Giorgi; C Longhini; F Portaluppi
Journal:  Int Urol Nephrol       Date:  2010-11-04       Impact factor: 2.370

Review 7.  Chronic kidney disease in the hypertensive patient: an overview of the I-DEMAND study.

Authors:  Giovanna Leoncini; Francesca Viazzi; Enrico Agabiti Rosei; Ettore Ambrosioni; Francesco V Costa; Gastone Leonetti; Achille C Pessina; Bruno Trimarco; Massimo Volpe; Giacomo Deferrari; Roberto Pontremoli
Journal:  High Blood Press Cardiovasc Prev       Date:  2011-03-01

Review 8.  Development of quality indicators for care of chronic kidney disease in the primary care setting using electronic health data: a RAND-modified Delphi method.

Authors:  Shingo Fukuma; Sayaka Shimizu; Kakuya Niihata; Ken-Ei Sada; Motoko Yanagita; Tsuguru Hatta; Masaomi Nangaku; Ritsuko Katafuchi; Yoshiro Fujita; Junji Koizumi; Shunzo Koizumi; Kenjiro Kimura; Shunichi Fukuhara; Yugo Shibagaki
Journal:  Clin Exp Nephrol       Date:  2016-05-04       Impact factor: 2.801

9.  Documentation and management of CKD in rural primary care.

Authors:  Maya K Rao; Cynthia D Morris; Jean P O'Malley; Melinda M Davis; Motomi Mori; Sharon Anderson
Journal:  Clin J Am Soc Nephrol       Date:  2013-01-31       Impact factor: 8.237

10.  Estimated GFR reporting is not sufficient to allow detection of chronic kidney disease in an Italian regional hospital.

Authors:  Giorgio Gentile; Maurizio Postorino; Raymond D Mooring; Luigi De Angelis; Valeria Maria Manfreda; Fabrizio Ruffini; Manuela Pioppo; Giuseppe Quintaliani
Journal:  BMC Nephrol       Date:  2009-09-01       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.